Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy

(1) Background: Neoadjuvant therapy is the main therapeutic strategy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, and the combination of trastuzumab and pertuzumab (HP) has become a routine treatment. How to predict and screen patients who are less likely to r...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiayi, Zhang, Shuang, Ye, Chen, Liu, Qian, Cheng, Yuanjia, Ye, Jingming, Liu, Yinhua, Duan, Xuening, Xin, Ling, Zhang, Hong, Xu, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877578/
https://www.ncbi.nlm.nih.gov/pubmed/35207749
http://dx.doi.org/10.3390/jpm12020261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877578/
https://www.ncbi.nlm.nih.gov/pubmed/35207749
http://dx.doi.org/10.3390/jpm12020261

Ejemplares similares